Medherant partners with Cycle Pharmaceuticals to develop new products
LONDON: Medherant Ltd, the transdermal drug delivery company, has entered into a partnership with Cycle Pharmaceuticals to develop new products using Medherant’s proprietary TEPI Patch technology. Mercia Asset Management PLC holds a 30.1% direct stake in Medherant Ltd. Under the terms of the partnership, Medherant will receive an initial upfront licence payment with an additional…